Compass Q2: Tovecimig Final ORR Reaches 18%, Cash Runway Into 2028
CMPX sits 20% above its 52-week low of $1.61.
Summary
Compass Therapeutics' Q2 2026 10-Q highlights improved final efficacy for tovecimig in biliary tract cancer, a cash runway into 2028, and progress across its broader pipeline.
Key Events · Earnings and Guidance · CMPX
-
Tovecimig Final ORR Improves to 18.0%
In the Phase 2/3 COMPANION-002 trial, tovecimig plus paclitaxel delivered a final ORR of 18.0% (20/111) versus 5.3% for paclitaxel alone, with the p-value strengthening to 0.0228. Median PFS reached 4.7 months compared with 2.6 months (HR=0.44, p<0.0001).
-
Cash Runway Extended Into 2028
Cash, cash equivalents, and marketable securities stood at $180 million as of June 30, 2026, a balance expected to fund operations into 2028. The net loss for Q2 was $25.2 million.
-
Pipeline Progress: CTX-8371 and CTX-10726
Phase 1 expansion cohorts for CTX-8371 are enrolling patients with TNBC, HL, and NSCLC. For CTX-10726, the Phase 1 dose-escalation study has dosed its first patients, with initial data anticipated in Q4 2026.
-
New Risk Factors Disclosed
The 10-Q adds risk factors concerning exclusive forum selection in the bylaws and potential adverse effects from macroeconomic conditions, tariffs, and geopolitical events.
Analysis · CMPX · Life Sciences
Compass Therapeutics posted a Q2 2026 net loss of $25.2 million, but the spotlight falls squarely on updated clinical data for lead asset tovecimig. In the Phase 2/3 COMPANION-002 trial for biliary tract cancer, the final overall response rate climbed to 18.0% (p=0.0228), accompanied by a highly significant progression-free survival advantage—4.7 months versus 2.6 months (HR=0.44). Meanwhile, expansion cohorts for CTX-8371 are now enrolling, and CTX-10726 has dosed its first patients. With $180 million in cash and marketable securities, the company's runway extends into 2028, easing near-term financing concerns. The filing also introduces new risk factors related to exclusive forum selection and macroeconomic or tariff impacts, but the clinical momentum remains the central takeaway.
At the time of this filing, CMPX was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $340.4M. The 52-week trading range was $1.61 to $6.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.